Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...
Although there have been several proof-of-concept studies suggesting DBS is effective in addictions, according to those ...
FOX 13 Tampa Bay on MSN6d
Trial date set for lawsuit against Publix claiming pharmacies contributed to nation's opioid crisisThe National Prescription Opiate Litigation in Cobb County, Georgia accuses a number of chain pharmacies, including Publix, ...
Pharmaceutical Technology on MSN1d
Latigo secures $150m for non-opioid pain treatment developmentLatigo has secured $150m in a Series funding round, which will be used to further the development of its Nav1.8 inhibitors.
The lawsuit claims Publix opioid sales increased while sales at competitors declined after they settled similar lawsuits. The trial is set for November in an Atlanta federal court and could have ...
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
Medical Device Network on MSN1d
VUMC and Rollins’ researchers develop model to detect NOWS in infantsVUMC and the Rollins School of Public Health have developed a predictive model to identify newborns at risk of severe NOWS.
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...
is a potential best-in-class non-opioid therapeutic candidate for the treatment of chronic pain. The Phase 1 trial is designed to evaluate the safety, tolerability, and pharmacokinetics of LTG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback